31May

No significant survival benefit of pembrolizumab over 2L paclitaxel in previusly treated PD-L1+ advanced gastric or gastroesophageal junction cancer

Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.


Abstract No : 4503

Abstract Type : Oral Abstract Session

Indication : Gastric or gastroesophageal junction cancer (GC)

Intervention : Pembrolizumab

Company : Merck & Co.

Technology : Immune Checkpoint Inhibitors (ICI)


Results:

At the time of this analysis, 366/395 patients with CPS $1 had died (92.6%). Pembrolizumab prolonged OS vs paclitaxel in PD-L1–positive patients (Table). No significant differences appeared between groups in PFS (Table). Objective response rate (ORR) was higher for pembrolizumab in the CPS $10 group, and DOR was longer with pembrolizumab using all CPS cutoffs (Table). There were fewer drug-related adverse events (AEs) with pembrolizumab than paclitaxel in the overall population (53% vs 84%).


Conclusion:

This long-term analysis found that second-line pembrolizumab prolonged OS among patients with PD-L1–positive GC and led to fewer drug-related AEs vs paclitaxel.


Commentary:

Interestingly, no significant survival benefit of pembrolizumab over 2L paclitaxel in previusly treated PD-L1+ advanced gastric or gastroesophageal junction cancer and similar findings seen in long term data as well presented in ASCO20. However, second-line pembrolizumab showed a trend toward prolonged OS among patients with PD-L1–positive gastric cancer.


Refer to Gastric Cancer Market report for detailed Insights.